The Next-Generation Immunotherapies conference will delve into the next frontier of immunotherapy development beyond Anti-PD-1/PD-L1 therapies. We invite speakers to examine strategies to target novel pathways, share updates on optimizing therapeutic window while minimizing toxicity for immunocytokines, multispecifics, and cell-based therapies. The debate between CARs and TILs will be highlighted, discussing off-the-shelf potential, toxicity management and improving persistence. Advances in engineered immune cells, cancer vaccines and the complexities of combination therapies will also be discussed. This conference aims to provide a forum for researchers to collaborate and discover the next breakthroughs in immunotherapy.

For more details on the conference, please contact:

Mimi Langley
Senior Conference Director
Cambridge Healthtech Institute
Phone: (+1) 781-972-5439
Email: mlangley@healthtech.com

For sponsorship information, please contact:

Companies A-K
Jason Gerardi
Sr. Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-972-5452
Email: jgerardi@healthtech.com

Companies L-Z
Ashley Parsons
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-972-1340
Email: ashleyparsons@healthtech.com

Conference Programs

• Display of Biologics
• Engineering Antibodies
• Machine Learning: Part 2

• Antibody-Based Therapies
• Emerging Targets & Approaches
• Membrane Protein Targets

• Safety & Efficacy
• Advancing Multispecifics
• Engineering Bispecifics

• Modulating the TME
• Innovative CAR T Therapy
• Next-Gen Immunotherapies

• Optimisation & Developability
• Analytical Characterisation
• Protein Stability & Formulation

• Data Science & Engineering
• Optimising Expression
• Process Development

• Intro to Machine Learning
• Machine Learning: Part 1
• Machine Learning: Part 2

• Antibody-Based Therapies
• Engineering Conjugates
• Next-Gen Immunotherapies

---